Corrigendum to “Discovery and lead optimisation of a potent, selective and orally bioavailable RARβ agonist for the potential treatment of nerve injury” [Bioorg. Med. Chem. Lett. 29(8) (2019) 995–1000]

Ítems similars

• Discovery and lead optimisation of a potent, selective and orally bioavailable RARβ agonist for the potential treatment of nerve injury
  per: Goncalves, Maria B., et al.
  Publicat: (2019)
• Corrigendum to “Metal-assisted synthesis of unsymmetrical magnolol and honokiol analogs and their biological assessment as GABA(A) receptor ligands” [Bioorg. Med. Chem. Lett. 25/2 (2015) 400–403]
  per: Rycek, Lukas, et al.
  Publicat: (2015)
• Recent advances in the design of RAR α and RAR β agonists as orally bioavailable drugs. A review
  per: Borthwick, Alan D., et al.
  Publicat: (2020)
• Corrigendum to “Challenges in the development of an M(4) PAM preclinical candidate: The discovery, SAR, and biological characterization of a series of azetidine-derived tertiary amides” [Bioorg. Med. Chem. Lett. 27(23) (2017) 5179-5184]
  per: Tarr, James C., et al.
  Publicat: (2018)
• Corrigendum to “Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): Preparation and evaluation of pyrazole linked analogues” [Bioorg. Med. Chem. Lett. 23 (2013) 6019–6024]
  per: Large, Jonathan M., et al.
  Publicat: (2014)